Novartis Eyes Companion Test To Restart Approval Path For Struggling Med
This article was originally published in The Gray Sheet
Executive Summary
Novartis has identified a genetic sequence that may be a risk factor for serious liver injury in patients receiving Prexige (lumiracoxib), a finding that may signal a path forward for the so-far troublesome development-stage COX-2 inhibitor